Transcoronary Infusion of Cardiac Progenitor Cells in Hypoplastic Left Heart Syndrome: 3-year Follow-up of the TICAP Trial
|
|
- Charleen Owen
- 5 years ago
- Views:
Transcription
1 Transcoronary Infusion of Cardiac Progenitor Cells in Hypoplastic Left Heart Syndrome: 3-year Follow-up of the TICAP Trial Shunji Sano, Shuta Ishigami, Takuya Goto, Daiki Ousaka, Suguru Tarui, Michihiro Okuyama, Sadahiko Arai, Kenji Baba, Shingo Kasahara, Shinichi Ohtsuki, Hidemasa Oh Okayama University, Okayama, Japan Department of Cardiovascular Surgery 1, Pediatrics 2, Regenerative Medicine, Center for Innovative Clinical Medicine AATS 95 th Annual Meeting,Seattle,2015
2 COI Disclosure The authors have no financial conflicts of interest to disclose concerning the presentation.
3 Long-term clinical outcome of hypoplastic left heart syndrome (HLHS) Semin Thorac Cardiovasc Surg. 2007;19(3): European Journal of Cardio- Thoracic Surgery 2014;46:
4 Cardiac regenerative therapy in recent years Non-Cardiac progenitors Cardiac progenitors Bone marrow cells Mesenchymal stem cells ips cells TOPCARE-AMI trial POSEIDON trial Skeletal myoblasts Cardiac progenitor cells Direct reprogramming MAGIC trial TICAP trial, PERSEUS trial SCIPIO trial CADUCEUS trial
5 TICAP (Transcoronary Infusion of CArdiac Progenitor cells) trial (Phase I) CDCs Objective The purpose of this clinical trial is to evaluate the feasibility and safety of cardiosphere-derived cell (CDC) infusion in children with HLHS. PERSEUS trial (Phase II) randomized study
6 Study design of TICAP phase 1 controlled trial 18 HLHS patients were eligible and enrolled 10 were constitutively allocated to receive CDC 3 exclude after surgery 1 : pacemaker implantation 1 : bacterial contamination 1 :lung infection 7 received CDCs, completed 3-year follow-up study 8 were prospectively assigned as control group 1 exclude Myocardial infarction after surgery 7 control patients completed 3-year follow-up study
7 Study timeline and procedures in this study Catheter and CDC infusion tissue harvesting intracoronary injection
8 Baseline characteristics in enrolled patients Control group (n=7) CDC-treated group (n=7) P value Age at operation 1.5 ± ± (years) Male sex 5 (71%) 4 (57%) 0.50 Body weight at 6.8 ± ± operation (kg) Morphology (HLHS) MA/AA 3 (43%) 3 (43%) 0.70 MS/AA 1 (14%) 2 (29%) 0.50 MA/AS 0 1 (14%) 0.50 MS/AS 2 (29%) Variant 1 (14%) 1 (14%) 0.77 BNP (pg/ml) 53.8 ± ±
9 Baseline characteristics in enrolled patients Control group (n=7) CDC-treated group (n=7) P value Surgical characteristics Norwood-Glenn 1 (14%) 1 (14%) 0.77 Bidirectional Glenn 4 (57%) 2 (29%) 0.29 TCPC 2 (29%) 4 (57%) 0.29 Concomitant procedures None 3 (43%) 3 (43%) 0.70 Arch augmentation 1 (14%) 1 (14%) 0.77 Tricuspid valve repair 1 (14%) 1 (14%) 0.77 Atrial septectomy 1 (14%) PA patch augmentation 1 (14%) 3 (43%) 0.28 CPB time (min) ± ± ACC time (min) 58.3 ± ±
10 Primary outcomes and adverse events during 36-month follow-up Control group (n=7) CDC-treated group (n=7) P value Adverse events Late failure NYHA class III-IV PLE/plastic bronchitis Takedown 0 0 Transplant 0 0 Death 0 0 Cardiopulmonary resuscitation SVT 0 0 Pacemaker implantation 0 0 Prolonged chest tube drainage Cirrhosis 0 0 Thromboembolic events 0 0 Stroke 0 0 Tumor formation 0 0
11 Adverse-event-free survival during 36-month follow-up
12 Incidence of catheter intervention during 36-month follow-up (N/person-year) Control CDC-treated P value group (n=7) group (n=7) Any type of unplanned catheter intervention APC coils Balloon angioplasty Pulmonary artery Aortic arch Fenestration
13 Freedom from catheter intervention during 36-month follow-up APC coil embolization All interventions
14 Myocardial ischemia and tumor marker analyses Tumor marker analyses at 36-month follow-up
15 RVEF on cmri (%) RVEDVI on cmri (ml/bsa 1.3 ) RVESVI on cmri (ml/bsa 1.3 ) Cardiac function analysis by cmri in CDC-treated and control patients RVEF RVEDVI RVESVI P=0.04 baseline months P=0.09 baseline months P=0.07 baseline months Between-group (control vs. CDC treated) comparisons, 2-way ANOVA was used to analyze the categorical independent variables between group and the time interaction term within group.
16 Cardiac function analysis by cmri during long-term follow-up baseline 1 year (+20%) 18 months (+18%) 36 months (+23%)
17 Ventricular stiffness and ventriculo-arterial coupling at final follow-up ventricular stiffness Ea/Ees
18 Heart failure status and somatic growth at 36-month follow-up BNP weight for age
19 Independent predictors of cardiac function improvements of CDC infusion age weight for age
20 Stronger regenerative ability of cardiac stem cells in young children (BBRC, 2007) (Circulation. 2012)
21 Independent predictors of cardiac function improvements of CDC infusion EF at baseline
22 Conclusions 1. Intracoronary infusion of autologous CDCs is feasible and safe to treat the children with hypoplastic left heart syndrome. 2. Improved ventricular function was maintained during 36 months of observation, which resulted in improvement of heart failure status in long term. 3. A phase 2(PERSEUS) trial is ongoing in our hospital to examine the potential effects of cardiac function improvements and the long-term benefits of clinical outcomes.
23 PERSEUS trial (n=34) Randomized assignment of patients 41 met initial eligibility criteria 7 excluded PERSEUS trial (n=34) 34 randomly assigned (1:1) 17 controls patients 17 CDCs-treated patients 5 pending analysis 17 control patients with 3-month F/U 12 CDCs-treated patients with 3-month F/U
24 Thank you very much! Hidemasa Oh Shuta Ishigami Suguru Tarui
25 Baseline characteristics of eligible patients in CDC and control groups (n=34) Control groups CDC-treated group (n=17) (n=17) Age at operation (ys) 2.7 ± ± 1.2 Male sex 11 8 Birth weight (g) 29511± ± 384 Body weight at operation (kg) 10.5± ± 2.4 Anatomic diagnosis Hypoplastic left heart syndrome 8 6 Non-HLHS 9 11 Moderate to severe TR 4 4 Ross score > grade III 4 4 BNP (pg/ml) 61.6 ± ± 38.4 History of Catheter interventions Type of surgical palliation Second-stage palliation 4 3 Third stage palliation 13 14
26 Ejection fraction on cmri (%) Ejection fraction on UCG (%) Ejection fraction on RVG (%) Cardiac function analysis in PERSEUS randomized-controlled study cardiac MRI UCG RVG P=0.12 P=0.02 P=0.16 P=0.006 P=0.42 P= controls CDCs controls 10 CDCs controls 10 CDCs baseline 3 months 3 baseline 3 months 3 months 0 0 baseline 3 months 3 baseline 3 months baseline 3 months 3 baseline 3 months 3
Okayama University research: Cell injections get to the heart of congenital defects
PRESS RELEASE Source: Okayama University, Center for Public Information For immediate release: 28 January 2015 Okayama University research: Cell injections get to the heart of congenital defects (Okayama,
More informationTranscoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: 3-year follow-up of the TICAP trial
Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: 3-year follow-up of the TICAP trial Suguru Tarui, MD, a Shuta Ishigami, MD, a Daiki Ousaka, RDCS, a Shingo Kasahara,
More informationClinical Track. Intracoronary Autologous Cardiac Progenitor Cell Transfer in Patients With Hypoplastic Left Heart Syndrome
Clinical Track Intracoronary Autologous Cardiac Progenitor Cell Transfer in Patients With Hypoplastic Left Heart Syndrome The TICAP Prospective Phase Controlled Trial Shuta Ishigami, Shinichi Ohtsuki,
More informationHybrid Therapy for Hypoplastic Left Heart Syndrome Myth, Alternative or Standard?
Hybrid Therapy for Hypoplastic Left Heart Syndrome Myth, Alternative or Standard? Can Yerebakan, Klaus Valeske, Hatem Elmontaser, Matthias Mueller, Juergen Bauer, Josef Thul, Dietmar Schranz, Hakan Akintuerk
More informationIntroduction. Study Design. Background. Operative Procedure-I
Risk Factors for Mortality After the Norwood Procedure Using Right Ventricle to Pulmonary Artery Shunt Ann Thorac Surg 2009;87:178 86 86 Addressor: R1 胡祐寧 2009/3/4 AM7:30 SICU 討論室 Introduction Hypoplastic
More informationDr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK
Advanced heart failure - devices, mechanical circulatory support and cardiac transplantation Monday 30 January 2017 Stem cell and gene therapies for heart failure Dr. Alexander Lyon Senior Lecturer and
More informationS. Bruce Greenberg, MD FNASCI and President, NASCI Professor of Radiology and Pediatrics University of Arkansas for Medical Sciences
S. Bruce Greenberg, MD FNASCI and President, NASCI Professor of Radiology and Pediatrics University of Arkansas for Medical Sciences No financial disclosures Aorta Congenital aortic stenosis/insufficiency
More informationWhat Can the Database Tell Us About Reoperation?
AATS/STS Congenital Heart Disease Postgraduate Symposium May 5, 2013 What Can the Database Tell Us About Reoperation? Jeffrey P. Jacobs, M.D. All Children s Hospital Johns Hopkins Medicine The Congenital
More informationImpact of Cardiac Progenitor Cells on Heart Failure and Survival in Single Ventricle Congenital Heart Disease
Impact of Cardiac Progenitor Cells on Heart Failure and Survival in Single Ventricle Congenital Heart Disease Toshikazu Sano, M.D. 1, Daiki Ousaka, Ph.D. 1, Takuya Goto, M.D. 1, Shuta Ishigami,M.D., Ph.D.
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationHybrid Stage I Palliation / Bilateral PAB
Hybrid Stage I Palliation / Bilateral PAB Jeong-Jun Park Dept. of Thoracic & Cardiovascular Surgery Asan Medical Center, University of Ulsan CASE 1 week old neonate with HLHS GA 38 weeks Birth weight 3.0Kg
More informationSurvival Rates of Children with Congenital Heart Disease continue to improve.
DOROTHY RADFORD Survival Rates of Children with Congenital Heart Disease continue to improve. 1940-20% 1960-40% 1980-70% 2010->90% Percentage of children with CHD reaching age of 18 years 1938 First Patent
More informationBiatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD
Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD Disclosures Consultant/Speaker AtriCure Medtronic CryoLife Edwards Abbott Research Funding Abbott Equity Interest Clear Catheter Cleveland Clinic
More informationManagement of complex CHD in adults
Management of complex CHD in adults Victor Tsang Society of Thoracic Surgeons of Thailand 2016 The impact of infant cardiac surgery Over 90 % of infants born with CHD will reach adulthood By 2010, adults
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationThe Double Switch Using Bidirectional Glenn and Hemi-Mustard. Frank Hanley
The Double Switch Using Bidirectional Glenn and Hemi-Mustard Frank Hanley No relationships to disclose CCTGA Interesting Points for Discussion What to do when. associated defects must be addressed surgically:
More informationThe Failing Systemic Right Ventricle European Society of Cardiology 2012
The Failing Systemic Right Ventricle European Society of Cardiology 2012 I have nothing to disclose. Is the right ventricle an inherently weaker ventricle? Functionally single ventricle TGA (after atrial
More informationLONG TERM OUTCOMES OF PALLIATIVE CONGENITAL HEART DISEASE
LONG TERM OUTCOMES OF PALLIATIVE CONGENITAL HEART DISEASE S Bruce Greenberg, MD, FACR, FNASCI Professor of Radiology and Pediatrics Arkansas Children's Hospital University of Arkansas for Medical Sciences
More informationSURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators ACC Late Breaking Clinical Trials March 16,
More informationSurgery For Ebstein Anomaly
Surgery For Ebstein Anomaly Christian Pizarro, MD Chief, Pediatric Cardiothoracic Surgery Director, Nemours Cardiac Center Alfred I. dupont Hospital for Children Professor of Surgery and Pediatrics Sidney
More informationManagement of Heart Failure in Adult with Congenital Heart Disease
Management of Heart Failure in Adult with Congenital Heart Disease Ahmed Krimly Interventional and ACHD consultant King Faisal Cardiac Center National Guard Jeddah Background 0.4% of adults have some form
More informationGlenn Shunts Revisited
Glenn Shunts Revisited What is a Super Glenn Patricia O Brien, MSN, CPNP-AC Nurse Practitioner, Pediatric Cardiology No Disclosures Single Ventricle Anatomy Glenn Shunt Cavopulmonary Anastomosis Anastomosis
More informationHypoplastic Left Heart Syndrome: Echocardiographic Assessment
Hypoplastic Left Heart Syndrome: Echocardiographic Assessment Craig E Fleishman, MD, FACC, FASE Director, Non-invasive Cardiac Imaging The Hear Center at Arnold Palmer Hospital for Children, Orlando SCAI
More informationc-kit Stem Cell Therapy of Ischemic Cardiomyopathy
American Heart Association Scientific Sessions American Heart Association Scientific Sessions c-kit Stem Cell Therapy of Ischemic Cardiomyopathy Roberto Bolli, M.D. Institute of Molecular Cardiology University
More informationCell Combination Therapy. Disclosures
Cell Combination Therapy Joshua M. Hare, M.D. Louis Lemberg Professor Senior Associate Dean Chief Science Officer Interdisciplinary Stem Cell Institute The Miller School of Medicine, University of Miami
More informationPulmonary Valve Replacement
Indications/Timing and Type of Interventions: Pulmonary Valve Replacement Lars Sondergaard, MD, DMSc Professor of Cardiology Rigshospitalet Copenhagen, Denmark Case 15 years old girl with tetralogy of
More informationTranslating Molecular Insights Into New Cellular Therapies For Cardiovascular Disease
Ottawa Hospital Research Institute Institute de recherche de l Hopital d Ottawa Translating Molecular Insights Into New Cellular Therapies For Cardiovascular Disease ACC Rockies March 11-14, 2012 Dr. Duncan
More informationCardiology Research Newsletter
in partnership with Cardiology Research Newsletter Fall 2016 Issue Six Percutaneous Approach to Correct Functional Mitral Regurgitation The AccuCinch clinical trial is an early feasibility study designed
More informationWhen to implant an ICD in systemic right ventricle?
When to implant an ICD in systemic right ventricle? Département de rythmologie et de stimulation cardiaque Nicolas Combes n.combes@clinique-pasteur.com Pôle de cardiologie pédiatrique et congénitale Risk
More informationLeitlinien. Hypoplastisches Linksherzsyndrom. Hypoplastic left heart syndrome (HLHS)
1.Title Hypoplastic left heart syndrome (HLHS) N.A. Haas, Bad Oeynhausen Ch. Jux, Giessen J. Photiadis, Berlin H.-H. Kramer, Kiel Typical forms: Mitral atresia/aortic atresia (MA/AoA) Mitral stenosis/aortic
More informationM/3, cc-tga, PS, BCPC(+) Double Switch Operation
2005 < Pros & Cons > M/3, cc-tga, PS, BCPC(+) Double Switch Operation Congenitally corrected TGA Atrio-Ventricular & Ventriculo-Arterial discordance Physiologically corrected circulation with the morphologic
More informationSurgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan
Surgical AF Ablation : Lesion Sets and Energy Sources What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan Disclosures Consultant/Advisory Board: Abbott, Edwards Lifesciences
More informationC1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders
C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders GENERAL ISSUES REGARDING MEDICAL FITNESS-FOR-DUTY 1. These medical standards apply to Union Pacific Railroad (UPRR) employees
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationShould Paroxysmal Atrial Fibrillation be Treated During Cardiac Surgery?
Should Paroxysmal Atrial Fibrillation be Treated During Cardiac Surgery? Patrick M. McCarthy MD, Adarsh Manjunath, BA, Jane Kruse, RN, BSN, Adin-Cristian Andrei, PhD, Zhi Li, MS, Edwin C. McGee, MD, S.
More informationLong-term results of a strategy of aortic valve repair in the paediatric population: Should we avoid cusp extension?
Long-term results of a strategy of aortic valve repair in the paediatric population: Should we avoid cusp extension? Y d Udekem, J Siddiqui, C Seaman, I Konstantinov, J Galati, M Cheung, C Brizard Royal
More informationCase Report. Stent Placement in a Neonate with Sano Modification of the Norwood using Semi-Elective Extracorporeal Membrane Oxygenation.
Stent Placement in a Neonate with Sano Modification of the Norwood using Semi-Elective Extracorporeal Membrane Oxygenation Mustafa Gulgun and Michael Slack Associated Profesor Children National Medical
More informationWIEF-AFF ROUNDTABLE Tokyo, Japan 26 May 2015
WIEF-AFF ROUNDTABLE 2015 Tokyo, Japan 26 May 2015 Regenerative Medicine Goal: - To restore organ +/- tissue function - For pts with serious injuries or chronic disease where the body unable to heal & restore
More informationLEFT VENTRICULAR OUTFLOW OBSTRUCTION WITH A VSD: OPTIONS FOR SURGICAL MANAGEMENT
LEFT VENTRICULAR OUTFLOW OBSTRUCTION WITH A VSD: OPTIONS FOR SURGICAL MANAGEMENT 10-13 March 2017 Ritz Carlton, Riyadh, Saudi Arabia Zohair AlHalees, MD Consultant, Cardiac Surgery Heart Centre LEFT VENTRICULAR
More informationPeripheral and Cardiology Coder 2018
Peripheral and Cardiology Coder 2018 Cardiovascular Services and Procedures Prepared and Published By: MedLearn Publishing A Division of MedLearn Media, Inc. 445 Minnesota Street, Suite 514 St. Paul, MN
More informationCoarctation of the aorta
T H E P E D I A T R I C C A R D I A C S U R G E R Y I N Q U E S T R E P O R T Coarctation of the aorta In the normal heart, blood flows to the body through the aorta, which connects to the left ventricle
More informationAbsent Pulmonary Valve Syndrome
Absent Pulmonary Valve Syndrome Fact sheet on Absent Pulmonary Valve Syndrome In this condition, which has some similarities to Fallot's Tetralogy, there is a VSD with narrowing at the pulmonary valve.
More informationJournal of the American College of Cardiology Vol. 52, No. 1, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 1, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.03.034
More informationDiagnostic & Therapeutic Cardiac Catheterization Coder 2017
Diagnostic & Therapeutic Cardiac Catheterization Coder 2017 Including peripheral and cardiovascular services and procedures Prepared and Published By: MedLearn Publishing A Division of Panacea Healthcare
More informationResearch Presentation June 23, Nimish Muni Resident Internal Medicine
Research Presentation June 23, 2009 Nimish Muni Resident Internal Medicine Research Question In adult patients with repaired Tetralogy of Fallot, how does Echocardiography compare to MRI in evaluating
More informationT who has survived first-stage palliative surgical management
Intermediate Procedures After First-Stage Norwood Operation Facilitate Subsequent Repair Richard A. Jonas, MD Department of Cardiac Surgery, Children s Hospital, Boston, Massachusetts Actuarial analysis
More informationORIGINAL ARTICLE. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 50 (2016) 298 303 doi:10.1093/ejcts/ezw124 Advance Access publication 26 April 2016 ORIGINAL ARTICLE Cite this article as: Kotani Y, Kasahara S, Fujii Y, Eitoku
More informationOutline. Congenital Heart Disease. Special Considerations for Special Populations: Congenital Heart Disease
Special Considerations for Special Populations: Congenital Heart Disease Valerie Bosco, FNP, EdD Alison Knauth Meadows, MD, PhD University of California San Francisco Adult Congenital Heart Program Outline
More informationPeri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)
Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY) Thomas Walther, Christian W. Hamm, Gerhard Schuler, Alexander Berkowitsch,
More informationPulmonary Regurgitation after TOF Repair. How to Assess and Options of Management? Worakan Promphan, MD.FSCAI.
Pulmonary Regurgitation after TOF Repair. How to Assess and Options of Management? Worakan Promphan, MD.FSCAI. Queen Sirikit National Institute of Child Health (QSNICH) Bangkok, Thailand How to Assess?
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More informationPediatric Echocardiography Examination Content Outline
Pediatric Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 Anatomy and Physiology Normal Anatomy and Physiology 10% 2 Abnormal Pathology and Pathophysiology
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACHD. See Adult congenital heart disease (ACHD) Adult congenital heart disease (ACHD), 503 512 across life span prevalence of, 504 506
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationChildren with Single Ventricle Physiology: The Possibilities
Children with Single Ventricle Physiology: The Possibilities William I. Douglas, M.D. Pediatric Cardiovascular Surgery Children s Memorial Hermann Hospital The University of Texas Health Science Center
More informationStem Cells. Keith Channon. Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford
Stem Cells Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford Adult Stem Cells Unique cells that are capable of self-renewal Have the ability to differentiate
More informationSurgical options for tetralogy of Fallot
Surgical options for tetralogy of Fallot Serban Stoica FRCS(CTh) MD ACHD study day, 19 September 2017 Anatomy Physiology Children Adults Complications Follow up Anatomy Etienne Fallot (1850-1911) VSD Overriding
More informationChapter 13 Worksheet Code It
Class: Date: Chapter 13 Worksheet 3 2 1 Code It True/False Indicate whether the statement is true or false. 1. A cardiac catheterization diverts blood from the heart to the aorta. 2. Selective vascular
More informationMid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum
Mid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum Kagami MIYAJI, MD, Akira FURUSE, MD, Toshiya OHTSUKA, MD, and Motoaki KAWAUCHI,
More informationCardiovascular Stem Cell Therapy
Cardiovascular Stem Cell Therapy Jeffrey A Southard, MD Assistant Clinical Professor, Medicine Division of Cardiovascular Medicine May 20, 2011 Cardiovascular Disease Effects 81.1 million Americans More
More information가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY
가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY PA c IVS (not only pulmonary valve disease) Edwards JE. Pathologic Alteration of the right heart. In: Konstam MA, Isner M, eds.
More informationAssessing the Impact on the Right Ventricle
Advances in Tricuspid Regurgitation Congress of the European Society of Cardiology (ESC) Munich, August 25-29, 2012 Assessing the Impact on the Right Ventricle Stephan Rosenkranz, MD Clinic III for Internal
More informationMid-term result of atrioventricular valve replacement in patients with a single ventricle
Interactive CardioVascular and Thoracic Surgery (2018) 1 6 doi:10.1093/icvts/ivy155 ORIGINAL ARTICLE Cite this article as: Sughimoto K, Hirata Y, Hirahara N, Miyata H, Suzuki T, Murakami A et al. Mid-term
More informationTHE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU
THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU Cardiology Dept. Rambam Health Care Campus Rappaport Faculty of Medicine Technion, Israel Why the Right Ventricle? Pulmonary hypertension (PH) Right
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationSupplemental Table 1 Clinical trials of cell-based cardiac repair without controls or with nonrandomized study design
Cell-Based Therapy for Myocar Ischemia and Infarction: Pathophysiological Mechanisms Supplemental Table 1 Clinical trials of cell-based cardiac repair without s or with nonrandom study design Head-tohead
More informationThe REDUCE LAP Heart Failure Trial. David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial David M Kaye
More informationVentricule Unique & Fuite de la Valve Atrioventriculaire: Quand Intervenir? Emre Belli Massy
Ventricule Unique & Fuite de la Valve Atrioventriculaire: Quand Intervenir? Emre Belli Massy CHD Atr ioventr icular valve r epair in patients with functional single-ventr icle physiology: Impact of ventr
More informationAppendix A.1: Tier 1 Surgical Procedure Terms and Definitions
Appendix A.1: Tier 1 Surgical Procedure Terms and Definitions Tier 1 surgeries AV Canal Atrioventricular Septal Repair, Complete Repair of complete AV canal (AVSD) using one- or two-patch or other technique,
More informationSummary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationCMR EVALUATION OF AORTO- PULMONARY COLLATERALS PRIOR TO FONTAN AND THEIR IMPACT ON EARLY OUTCOME
XLIII CONGRESSO NAZIONALE SOCIETÀ ITALIANA DI CARDIOLOGIA PEDIATRICA Padova 16-19 Ottobre 2013 L.Ait-Ali, L. Arcieri, V. Pak, R. Moschetti, P. Festa. Istiituto di fisiologia clinica CNR Massa U.O. Cardiologia
More informationSite of Interstage Care, Resource Utilization, and Interstage Mortality: A Report from the NPC-QIC Registry
Schidlow et al 1 Site of Interstage Care, Resource Utilization, and Interstage Mortality: A Report from the NPC-QIC Registry David Schidlow Kimberlee Gauvreau Mehul Patel Karen Uzark David W. Brown For
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationCatheter-based mitral valve repair MitraClip System
Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationThe Counter HF Clinical Study for Heart Failure
The Counter HF Clinical Study for Heart Failure CAUTION: C-Pulse is an investigational device. It is limited by Federal (or United States) Law to investigational use only. 13-111-B Agenda Heart Failure
More informationDown Syndrome Medical Interest Group Friday, 12 June Cardiac Surgery in patients with Down Syndrome
Down Syndrome Medical Interest Group Friday, 12 June 2015 Cardiac Surgery in patients with Down Syndrome Mr. Attilio Lotto, FRCS CTh Congenital Cardiac Surgeon Cardiac surgery in patients with Down syndrome
More informationPolicy Specific Section: May 16, 1984 April 9, 2014
Medical Policy Heart Transplant Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Transplant Original Policy Date: Effective Date: May 16, 1984 April 9, 2014 Definitions
More informationSpecific Basic Standards for Osteopathic Fellowship Training in Cardiology
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology American Osteopathic Association and American College of Osteopathic Internists BOT 07/2006 Rev. BOT 03/2009 Rev. BOT 07/2011
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationDavid Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR
David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS Peripheral Complications of TAVR TAVR Complications Reported Complications Rates range from 8% to 15% Predictors of
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationSummary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6
Summary Protocol REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6 Background: Epidemiology In 2002, it was estimated that approximately 900,000 individuals in the United Kingdom had a diagnosis
More informationEvaluation of the Right Ventricle and Risk Stratification for Sudden Cardiac Death
Evaluation of the Right Ventricle and Risk Stratification for Sudden Cardiac Death Presenters: Sabrina Phillips, MD FACC FASE Director, Adult Congenital Heart Disease Services The University of Oklahoma
More informationTranscatheter Echo Guided Mitral Valve Repair with NeoChord Implantation: Results from NeoChord Independent International Registry
Transcatheter Echo Guided Mitral Valve Repair with NeoChord Implantation: Results from NeoChord Independent International Registry A. Colli, E. Bizzotto, E. Manzan, L. Besola, F. Zucchetta, D.Pittarello,
More informationChronic Primary Mitral Regurgitation
Chronic Primary Mitral Regurgitation The Case For Early Surgical Intervention William K. Freeman, MD, FACC, FASE DISCLOSURES Relevant Financial Relationship(s) None Off Label Usage None Watchful Waiting......
More informationCY2015 Hospital Outpatient: Endovascular Procedure APCs and Complexity Adjustments
CY2015 Hospital Outpatient: Endovascular Procedure APCs Complexity Adjustments Comprehensive Ambulatory Payment Classifications (c-apcs) CMS finalized the implementation of 25 Comprehensive APC to further
More information9/8/2009 < 1 1,2 3,4 5,6 7,8 9,10 11,12 13,14 15,16 17,18 > 18. Tetralogy of Fallot. Complex Congenital Heart Disease.
Current Indications for Pediatric CTA S Bruce Greenberg Professor of Radiology Arkansas Children s Hospital University of Arkansas for Medical Sciences greenbergsbruce@uams.edu 45 40 35 30 25 20 15 10
More informationIntracoronary bone marrow cell application for terminal heart failure in children
Cardiology in the Young (2012), 22, 558 563 doi:10.1017/s1047951112000066 r Cambridge University Press, 2012 Original Article Intracoronary bone marrow cell application for terminal heart failure in children
More informationPolicy Specific Section: March 30, 2012 March 7, 2013
Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:
More informationThe Jay Cohn Lecture 2012: Therapeutic regeneration of the injured heart
The Jay Cohn Lecture 2012: Therapeutic regeneration of the injured heart Eduardo Marbán, M.D., Ph.D. Director, Cedars-Sinai Heart Institute Los Angeles, CA Disclosure: founder & stockholder, Capricor Inc.
More informationPercutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update
Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update T. Lefèvre Natural History of Aortic Stenosois 100 Latent period Survival (%) 80 60 40 20 Symptoms Average Age Death 0 40 50
More informationDeborah Kozik, DO Assistant Professor Division of Cardiothoracic Surgery s present: Early Repair Era
Deborah Kozik, DO Assistant Professor Division of Cardiothoracic Surgery 1954 1960: Experimental Era 1960 s 1980 s: Palliation Era 1980 s present: Early Repair Era 2010 2030 s: Fetal Interventions Hybrid
More informationClinical trial and real-world outcomes of an endovascular iliac aneurysm repair with the GORE Iliac Branch Endoprosthesis (IBE)
Clinical trial and real-world outcomes of an endovascular iliac aneurysm repair with the GORE Iliac Branch Endoprosthesis (IBE) Jan MM Heyligers, PhD, FEBVS Consultant Vascular Surgeon The Netherlands
More informationTetralogy of Fallot Latest data in risk stratification and replacement of pulmonic valve
Tetralogy of Fallot Latest data in risk stratification and replacement of pulmonic valve Alexandra A Frogoudaki Adult Congenital Heart Clinic Second Cardiology Department ATTIKON University Hospital No
More information